The advent of antibody-drug conjugates (ADCs) changed targeted cancer therapy by enabling the delivery of cytotoxic agents to cancer cells. Topoisomerase I inhibitors are commonly used as payloads in TROP2-directed ADCs, but they are linked to toxicity and emerging resistance. Degrader-antibody conjugates (DACs) go beyond conventional cytotoxic payloads by combining antigen targeting and selective protein degradation.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new BCL6 degradation inducers potentially useful for the treatment of autoimmune disease and cancer.
Shanghai Helioson Pharmaceutical Co. Ltd. has patented molecular glue degraders comprising cereblon (CRBN) binding agents acting as proto-oncogene Vav (VAV1) degradation inducers found to be potentially useful for the treatment of autoimmune disease and cancer.
